Cipla launches CipAir®: AI-Powered App Revolutionizing Asthma Screening in India Kumar Jeetendra | December 18, 2024 Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as “Cipla” today announced the launch of CipAir®️, a mobile application designed to enable timely and convenient first line of screening for asthma in India. This first-of-its-kind technology is clinically validated through a multi-centric pan-India study. It aims to empower people by helping them understand their …
Cipla Launches HUENA®, India’s First Non-Antibiotic UTI Drug Kumar Jeetendra | September 8, 2025 Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) today announced the launch of Methenamine Hippurate, a non-antibiotic treatment for patients suffering from recurrent urinary tract infections (UTIs), under the brand name HUENA. This marks a significant step forward for Cipla in the fight against Anti-Microbial Resistance (AMR) and reinforces its commitment …
